docetaxel anhydrous has been researched along with Melanoma in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (13.79) | 18.2507 |
| 2000's | 17 (29.31) | 29.6817 |
| 2010's | 27 (46.55) | 24.3611 |
| 2020's | 6 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Aglianò, AM; Carradori, S; D'Ascenzio, M; De Monte, C; Giantulli, S; Guglielmi, P; Mollica, A; Morrone, S; Scarpa, S; Secci, D; Silvestri, I | 1 |
| Arnst, KE; Banerjee, S; Deng, S; Kumar, G; Li, GB; Li, W; Miller, DD; Wang, Y; White, SW; Yang, J; Yang, L | 1 |
| Bąk, W; Bargieł, J; Cabaj, J; Góralczyk, A; Grabarska, A; Wróblewska-Łuczka, P; Łuszczki, JJ | 1 |
| Góralczyk, A; Grabarska, A; Marzęda, P; Wróblewska-Łuczka, P; Łuszczki, JJ | 1 |
| Góralczyk, A; Wróblewska-Łuczka, P; Łuszczki, JJ | 2 |
| Asher, R; Brant, R; Collins, L; Cutts, A; Gupta, A; Hodgson, DR; Love, S; Macaulay, VM; Middleton, MR; Myers, K; Schuh, A; Sharpe, A; Smith, P; Towers, C; Willenbrock, F; Wise, A | 1 |
| Hafner, M; Klicks, J; Rudolf, R; Schäfer, MEA | 1 |
| Du, H; Ji, J; Khan, AR; Liu, M; Yu, A; Zhai, G | 1 |
| Ji, J; Khan, AR; Lin, G; Liu, M; Zhai, G; Zhao, X | 1 |
| Ding, C; Hu, B; Jiang, L; Li, Z; Loh, XJ; Luo, Z; Wu, YL | 1 |
| Harada, K; Hirayama, M; Irisawa, R; Kato, Y; Mae, K; Saito, M; Tsuboi, R | 1 |
| Hafner, M; Klicks, J; Kluth, A; Maßlo, C; Rudolf, R | 1 |
| Golmohammadzadeh, S; Hanafi-Bojd, MY; Jaafari, MR; Malaekeh-Nikouei, B; Mosallaei, N | 1 |
| Dorval, T; Lantz, O; Louis, D; Milder, M; Péguillet, I; Piperno-Neumann, S; Scholl, SM; Vincent-Salomon, A | 1 |
| Asher, R; Collins, L; Danson, S; Gupta, A; Larkin, JM; Lisle, R; Lorigan, P; Love, S; Middleton, MR; Nathan, PD; Ottensmeier, CH; Plummer, R; Schuh, A; Shanyinde, M; Wise, A | 1 |
| Hassanzadeh, F; Javanmard, SH; Rostami, M; Taymouri, S; Varshosaz, J | 1 |
| Chen, C; Chmielowski, B; Ernst, S; Gonzalez, R; Jie, F; Keating, A; Kudchadkar, R; Redman, BG; Steinberg, J; Weber, J | 1 |
| Ahn, JB; Choi, HJ; Chung, HC; Heo, SJ; Jung, M; Kim, HR; Kim, HS; Lee, CK; Rha, SY; Roh, MR; Shin, SJ | 1 |
| Suo, YR; Xu, HM; Yang, YJ | 1 |
| Dana, N; Haghjooy Javanmard, S; Hassanzadeh, F; Taymouri, S; Varshosaz, J | 1 |
| Alani, AWG; Alany, RG; Chagani, SE; Doddapaneni, BS; Indra, AK; Kyryachenko, S; Rao, DA | 1 |
| Blanco, E; Deng, Z; Ferrari, M; Hu, TY; Liu, X; Mi, Y; Mu, C; Shen, H; Wolfram, J | 1 |
| Hersey, P; Mhaidat, NM; Thorne, R; Zhang, XD | 1 |
| Bedikian, AY; Camacho, LH; Frost, AM; Hernandez, IM; Hwu, P; Hwu, WJ; Jack, MA; Kim, KB; Ng, C; Papadopoulos, NE | 1 |
| Chang, PN; Lee, DT; Ling, MT; Wong, YC; Yap, WN; Yap, YL | 1 |
| Hersey, P; Jiang, CC; Thorne, RF; Yang, F; Zhang, XD; Zhu, BK | 1 |
| Fan, W; Hu, Y; Li, X; Lu, X; Xu, H; Zheng, D | 1 |
| Clark, JI; Gajewski, TF; Locke, F | 1 |
| Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C | 1 |
| Croft, A; Hersey, P; Jiang, CC; Liu, H; Tay, KH; Thorne, RF; Tseng, HY; Yang, F; Zhang, XD | 1 |
| Ievleva, AG; Imianitov, EN; Moiseenko, VM; Protsenko, SA; Zhabina, AS | 1 |
| Battista, A; Beuselinck, B; Brega, N; Courtney, R; de Jonge, MJ; Dumez, H; Kitzen, JJ; Schöffski, P; Verweij, J | 1 |
| Juan, Z; Liu, C; Liu, D; Liu, Z; Wang, L; Zhang, N | 1 |
| Kaneko, N; Kita, A; Kiyonaga, F; Nakahara, T; Sasamata, M; Takeuchi, M; Yamanaka, K; Yamauchi, T | 1 |
| Eroglu, Z; Fruehauf, JP; Jakowatz, JG; Kong, KM; Samlowski, W | 1 |
| Gallardo, HF; Gregor, P; Huang, QD; Morris, MJ; Rasalan, TS | 1 |
| Bahleda, R; Blay, JY; Dieras, V; LoRusso, P; Macaulay, VM; Mery-Mignard, D; Middleton, MR; Protheroe, AS; Sessa, C; Soria, JC; Tolcher, A | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kosmidis, P; Mylonakis, N; Samonis, G; Skarlos, DV; Stathopoulos, G | 1 |
| Dicker, AP; Grant, DS; Williams, TL; Zahaczewsky, M | 1 |
| Aydiner, A; Camlica, H; Kurul, S; Tas, F; Topuz, E | 1 |
| Benimetskaya, L; Hua, E; Khvorova, A; Lai, JC; Miller, P; Stein, CA; Wu, S; Zhang, LM | 1 |
| Fruehauf, JP; Jakowatz, JG; Kong, KM | 1 |
| Hersey, P; Kiejda, KA; Mhaidat, NM; Wang, Y; Zhang, XD | 1 |
| Hersey, P; Jiang, CC; Mhaidat, NM; Zhang, XD | 1 |
| Haas, HS; Heintz, E; Ingolic, E; Pfragner, R; Schauenstein, K; Schraml, E; Siegl, V | 1 |
| Hersey, P; Mhaidat, NM; Thorne, RF; Zhang, XD | 1 |
| de Bock, CE; Hersey, P; Mhaidat, NM; Thorne, RF; Zhang, XD | 1 |
| Contractor, R; Haass, NK; Herlyn, M; Medina, CA; Nathanson, KL; Nguyen, TK; Smalley, KS; Sproesser, K | 1 |
| Bissery, MC; Dykes, DJ; Harrison, SD; Waud, WR | 1 |
| Aamdal, S; Catimel, G; Sternberg, C; Sulkes, A; van Hoesel, Q; Verweij, J; Wolff, I | 1 |
| Aamdal, S; Franklin, HR; Kaplan, S; Kerger, J; Paridaens, R; Schachter, J; Verweij, J; Wanders, J; Wolff, I | 1 |
| Bedikian, AY; Burris, HA; Buzaid, AC; Eckardt, JR; Eton, O; Jenkins, J; Legha, SS; Smetzer, L; Von Hoff, DD; Weiss, GR | 1 |
| Battafarano, DF; Burris, HA; Keeling, JH; Older, SA; Zimmerman, GC | 1 |
| Coatsworth, S; Einzig, AI; Recio, A; Rodriquez, R; Schuchter, LM; Wiernik, PH | 1 |
| Bhuyan, BK; Lopes, NM; Miller, HP; Young, ND | 1 |
| Orel, NF | 1 |
| Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D | 1 |
1 review(s) available for docetaxel anhydrous and Melanoma
| Article | Year |
|---|---|
[Taxotere in various solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1998 |
17 trial(s) available for docetaxel anhydrous and Melanoma
| Article | Year |
|---|---|
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Docetaxel; Drug Resistance, Neoplasm; Dual-Specificity Phosphatases; Humans; MAP Kinase Kinase Kinases; Melanoma; Mitogen-Activated Protein Kinase Phosphatases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ets; Transcriptome | 2020 |
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; Double-Blind Method; GTP Phosphohydrolases; Humans; Kaplan-Meier Estimate; Male; Melanoma; Membrane Proteins; Middle Aged; Proportional Hazards Models; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Taxoids; Treatment Outcome | 2014 |
A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Naphthoquinones; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Treatment Outcome | 2015 |
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Patient Compliance; Taxoids; Young Adult | 2015 |
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Studies; Dacarbazine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neutropenia; Pulmonary Embolism; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome | 2009 |
A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Melanoma; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Taxoids; Treatment Outcome; Young Adult | 2010 |
Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Gastrointestinal Stromal Tumors; Humans; Maximum Tolerated Dose; Melanoma; Neoplasms; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Research Design; Safety; Taxoids; Treatment Outcome | 2011 |
Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Docetaxel; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2011 |
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Melanoma; Middle Aged; Quinazolines; Receptor, IGF Type 1; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2013 |
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Analysis; Taxoids | 2002 |
Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Docetaxel and vinorelbine plus GM-CSF in malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Melanoma; Neoplasm Staging; Recombinant Proteins; Taxoids; Vinblastine; Vinorelbine | 2005 |
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Head and Neck Neoplasms; Humans; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Sarcoma; Stomach Neoplasms; Taxoids | 1995 |
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Taxoids | 1994 |
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Taxoids | 1995 |
Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Taxoids | 1996 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Skin Neoplasms; Taxoids; Temozolomide; Thrombocytopenia | 2002 |
40 other study(ies) available for docetaxel anhydrous and Melanoma
| Article | Year |
|---|---|
Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Kinesins; Male; Melanoma; Mice; Molecular Structure; Neoplasms, Experimental; Prostatic Neoplasms; Small Molecule Libraries; Structure-Activity Relationship; Thiadiazoles | 2015 |
Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
Topics: Animals; Apoptosis; Binding Sites; Colchicine; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple; Heterografts; Humans; Male; Melanoma; Polymerization; Prostatic Neoplasms; Pyrimidines; Tubulin | 2018 |
Additive Interactions between Betulinic Acid and Two Taxanes in In Vitro Tests against Four Human Malignant Melanoma Cell Lines.
Topics: Antineoplastic Agents; Betulinic Acid; Cell Line; Docetaxel; Humans; In Vitro Techniques; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Pentacyclic Triterpenes; Skin Neoplasms; Taxoids | 2022 |
Fraxetin Interacts Additively with Cisplatin and Mitoxantrone, Antagonistically with Docetaxel in Various Human Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cisplatin; Docetaxel; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mitoxantrone | 2022 |
Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cisplatin; Cytostatic Agents; Docetaxel; Epirubicin; Humans; Melanoma; Mitoxantrone; Paclitaxel; Vemurafenib | 2023 |
Daphnetin, a Coumarin with Anticancer Potential against Human Melanoma: In Vitro Study of Its Effective Combination with Selected Cytostatic Drugs.
Topics: Cisplatin; Coumarins; Cytostatic Agents; Docetaxel; Epirubicin; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mitoxantrone; Vemurafenib | 2023 |
Preparation, Drug Treatment, and Immunohistological Analysis of Tri-Culture Spheroid 3D Melanoma-Like Models.
Topics: Antineoplastic Agents; Cell Line, Tumor; Coculture Techniques; Docetaxel; Fibroblasts; Humans; Keratinocytes; Melanoma; Skin Neoplasms; Spheroids, Cellular | 2021 |
Redox/enzyme sensitive chondroitin sulfate-based self-assembled nanoparticles loading docetaxel for the inhibition of metastasis and growth of melanoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Chondroitin Sulfates; Docetaxel; Drug Carriers; Drug Delivery Systems; Melanoma; Mice; Nanoparticles; Oxidation-Reduction; Rats; Rats, Wistar; Taxoids | 2018 |
Crosslinked self-assembled nanoparticles for chemo-sonodynamic combination therapy favoring antitumor, antimetastasis management and immune responses.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chlorophyllides; Chondroitin Sulfates; Combined Modality Therapy; Docetaxel; Melanoma; Mice, Inbred C57BL; Nanoparticles; Porphyrins; Thioctic Acid; Ultrasonic Therapy | 2018 |
Surfactant Free Delivery of Docetaxel by Poly[(R)-3-hydroxybutyrate-(R)-3-hydroxyhexanoate]-Based Polymeric Micelles for Effective Melanoma Treatments.
Topics: 3-Hydroxybutyric Acid; Animals; Caproates; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Drug Liberation; Hemolysis; Humans; Melanoma; Mice; Mice, Nude; Micelles; Polyethylene Glycols; Polymers; Prohibitins; Surface-Active Agents; Transplantation, Heterologous | 2018 |
Collision tumour of extramammary Paget disease and melanoma.
Topics: Administration, Intravenous; Aged; Asian People; Docetaxel; Fatal Outcome; Humans; Keratin-7; Male; MART-1 Antigen; Melanoma; Neoplasm Metastasis; Neoplasms, Second Primary; Paget Disease, Extramammary; Scrotum; Skin Neoplasms; Tubulin Modulators | 2019 |
A novel spheroid-based co-culture model mimics loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced selection of ABCB5-expressing cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Culture Techniques; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Coculture Techniques; Docetaxel; Fibroblasts; Humans; Keratinocytes; Melanoma; Spheroids, Cellular | 2019 |
Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colon; Colorectal Neoplasms; Docetaxel; Drug Carriers; Female; Humans; Lipids; Melanoma; Mice; Mice, Inbred BALB C; Nanoparticles; Rectum; Taxoids | 2013 |
High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Vaccines; CD4-Positive T-Lymphocytes; Cell Differentiation; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Leukapheresis; Melanoma; Neoadjuvant Therapy; T-Lymphocyte Subsets; Taxoids; Uveal Neoplasms | 2014 |
Self-assembly micelles with lipid core of cholesterol for docetaxel delivery to B16F10 melanoma and HepG2 cells.
Topics: Cell Survival; Cholesterol; Docetaxel; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Melanoma; Micelles; Structure-Activity Relationship; Taxoids | 2015 |
Raspberry pulp polysaccharides inhibit tumor growth via immunopotentiation and enhance docetaxel chemotherapy against malignant melanoma in vivo.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Docetaxel; Female; Humans; Interleukin-2; Melanoma; Melanoma, Cutaneous Malignant; Mice; Mice, Inbred C57BL; Plant Extracts; Polysaccharides; Rubus; Skin Neoplasms; Taxoids; Tumor Burden; Tumor Necrosis Factor-alpha; Waste Products | 2015 |
Optimisation of processing variables effective on self-assembly of folate targeted Synpronic-based micelles for docetaxel delivery in melanoma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cholesterol; Docetaxel; Drug Carriers; Folic Acid; Melanoma; Mice; Micelles; Polymers; Taxoids | 2015 |
A three-drug nanoscale drug delivery system designed for preferential lymphatic uptake for the treatment of metastatic melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Chromones; Docetaxel; Drug Carriers; Drug Compounding; Drug Resistance, Neoplasm; Everolimus; Humans; Lactones; Lymph Nodes; Melanocytes; Melanoma; Mice, Transgenic; Morpholines; Nanoparticles; Nanotechnology; Polyethylene Glycols; Skin Neoplasms; Solubility; Surface Properties; Taxoids; Time Factors; Tumor Burden | 2015 |
A Micro/Nano Composite for Combination Treatment of Melanoma Lung Metastasis.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Drug Synergism; Humans; Inhibitory Concentration 50; Lactic Acid; Liposomes; Lung Neoplasms; Melanoma; Mice, Nude; Microtechnology; Nanocomposites; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; RNA, Small Interfering; Taxoids; Tissue Distribution; Treatment Outcome | 2016 |
Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Cell Line, Tumor; Docetaxel; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Endoribonucleases; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinase 5; Melanoma; Protein Kinase C; Protein Serine-Threonine Kinases; Signal Transduction; Taxoids; TNF Receptor-Associated Factor 2 | 2008 |
Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cadherins; Cell Line, Tumor; Cell Proliferation; Chromans; Dacarbazine; Docetaxel; Humans; JNK Mitogen-Activated Protein Kinases; Melanoma; Neoplasm Invasiveness; Signal Transduction; Taxoids; Vitamin E | 2009 |
Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Humans; Melanoma; Membrane Potential, Mitochondrial; Microtubules; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Regulatory Factor X Transcription Factors; Signal Transduction; Stress, Physiological; Taxoids; Thapsigargin; Transcription Factors; Tunicamycin; Vincristine; X-Box Binding Protein 1 | 2009 |
Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane Permeability; Cell Shape; Cell Survival; Docetaxel; Drug Delivery Systems; Male; Melanoma; Membrane Potentials; Mice; Mice, Inbred ICR; Microscopy, Atomic Force; Microscopy, Electron, Transmission; Nanoparticles; Taxoids | 2009 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome | 2010 |
Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
Topics: Apoptosis; Cell Line, Tumor; Cytoprotection; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Taxoids; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Tumor Suppressor Protein p53; Up-Regulation | 2010 |
[Frequency of expression of markers predictive of sensitivity to cytostatics in skin melanoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cytostatic Agents; Docetaxel; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Middle Aged; Protein-Tyrosine Kinases; Pyrimidines; Skin Neoplasms; Taxoids | 2010 |
Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Compounding; Drug Delivery Systems; Excipients; Female; Formazans; Humans; Lecithins; Lipids; Melanoma; Mice; Nanoparticles; Neoplasms; Ovarian Neoplasms; Particle Size; Suspensions; Taxoids; Tetrazolium Salts; Tissue Distribution | 2011 |
Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Caspase 7; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Male; Melanoma; Mice; Mice, Nude; Naphthoquinones; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Survivin; Taxoids; Xenograft Model Antitumor Assays | 2011 |
A case report of putative autoimmunity to prostate cancer after immune-mediated rejection of melanoma through a shared tumor antigen.
Topics: Adenocarcinoma; Aged, 80 and over; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Docetaxel; Fatal Outcome; Glutamate Carboxypeptidase II; Humans; Immunotherapy; Male; Melanoma; Neoplasm Metastasis; Neoplasms, Second Primary; Prostate-Specific Antigen; Prostatic Neoplasms; Skin Neoplasms; Taxoids | 2012 |
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).
Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Capillaries; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Division; Cells, Cultured; Chemotaxis; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endothelium, Vascular; Fibrosarcoma; Glioblastoma; Humans; Lung Neoplasms; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Rats; Taxoids; Tumor Cells, Cultured; Umbilical Veins; Xenograft Model Antitumor Assays | 2003 |
Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Melanoma; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms; Taxoids; Thapsigargin; Thionucleotides; Tumor Cells, Cultured | 2004 |
Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase 2; Caspase Inhibitors; Cell Nucleus; Cysteine Endopeptidases; Cytochromes c; Docetaxel; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Humans; Melanoma; Membrane Potential, Mitochondrial; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation-Sensitizing Agents; RNA, Small Interfering; Taxoids; Transfection; Tumor Cells, Cultured | 2007 |
Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 2; Cell Line, Tumor; Docetaxel; Enzyme Activation; Genes, bcl-2; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Oncogene Protein v-akt; p38 Mitogen-Activated Protein Kinases; Taxoids | 2007 |
The non-competitive metabotropic glutamate receptor-1 antagonist CPCCOEt inhibits the in vitro growth of human melanoma.
Topics: Antineoplastic Agents; Cell Proliferation; Chromones; Docetaxel; Drug Resistance, Neoplasm; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Melanoma; Receptors, Metabotropic Glutamate; Skin Neoplasms; Taxoids; Tumor Cells, Cultured | 2007 |
Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Docetaxel; Humans; Isoenzymes; MAP Kinase Kinase 4; Melanoma; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Kinase C-delta; Protein Kinase C-epsilon; Skin Neoplasms; Taxoids; Tubulin | 2007 |
Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Docetaxel; Flow Cytometry; Humans; Melanoma; RNA, Small Interfering; Taxoids; Tubulin | 2008 |
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytostatic Agents; Cytotoxins; Docetaxel; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique; Humans; In Situ Nick-End Labeling; Melanoma; Mice; Mice, SCID; Nucleic Acid Hybridization; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere).
Topics: Animals; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Docetaxel; Drugs, Investigational; Female; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids; Transplantation, Heterologous | 1995 |
Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases.
Topics: Aged; Alopecia; Antineoplastic Agents, Phytogenic; Docetaxel; Edema; Female; Humans; Leg; Leiomyosarcoma; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Scleroderma, Localized; Taxoids | 1995 |
Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Assay; Cattle; Cells, Cultured; Dimethyl Sulfoxide; Docetaxel; Drug Screening Assays, Antitumor; In Vitro Techniques; Melanoma; Mice; Microtubule-Associated Proteins; Mitosis; Paclitaxel; Taxoids | 1997 |